NYSE:CO

Stock Analysis Report

Executive Summary

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China.


Snowflake Analysis

Flawless balance sheet and undervalued.


Similar Companies

Share Price & News

How has Global Cord Blood's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.3%

CO

-4.1%

US Healthcare

-2.8%

US Market


1 Year Return

-61.0%

CO

-8.9%

US Healthcare

-15.9%

US Market

Return vs Industry: CO underperformed the US Healthcare industry which returned -6.5% over the past year.

Return vs Market: CO underperformed the US Market which returned -15.1% over the past year.


Shareholder returns

COIndustryMarket
7 Day-2.3%-4.1%-2.8%
30 Day-27.3%-19.5%-18.8%
90 Day-44.3%-21.2%-24.0%
1 Year-61.0%-61.0%-7.7%-8.9%-14.2%-15.9%
3 Year-59.5%-59.9%13.1%8.1%9.9%2.8%
5 Year-47.8%-48.3%16.7%8.8%27.2%13.3%

Price Volatility Vs. Market

How volatile is Global Cord Blood's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Global Cord Blood undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CO ($2.91) is trading below our estimate of fair value ($19.87)

Significantly Below Fair Value: CO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CO is good value based on its PE Ratio (5.4x) compared to the Healthcare industry average (19.4x).

PE vs Market: CO is good value based on its PE Ratio (5.4x) compared to the US market (12.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CO is good value based on its PB Ratio (0.7x) compared to the US Healthcare industry average (2.3x).


Next Steps

Future Growth

How is Global Cord Blood forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Global Cord Blood has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Global Cord Blood performed over the past 5 years?

34.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CO has high quality earnings.

Growing Profit Margin: CO's current net profit margins (39.6%) are higher than last year (23.8%).


Past Earnings Growth Analysis

Earnings Trend: CO's earnings have grown significantly by 34.4% per year over the past 5 years.

Accelerating Growth: CO's earnings growth over the past year (101.6%) exceeds its 5-year average (34.4% per year).

Earnings vs Industry: CO earnings growth over the past year (101.6%) exceeded the Healthcare industry 14%.


Return on Equity

High ROE: CO's Return on Equity (12.4%) is considered low.


Next Steps

Financial Health

How is Global Cord Blood's financial position?


Financial Position Analysis

Short Term Liabilities: CO's short term assets (CN¥5.5B) exceed its short term liabilities (CN¥595.1M).

Long Term Liabilities: CO's short term assets (CN¥5.5B) exceed its long term liabilities (CN¥2.7B).


Debt to Equity History and Analysis

Debt Level: CO is debt free.

Reducing Debt: CO has no debt compared to 5 years ago when its debt to equity ratio was 57.9%.

Debt Coverage: CO has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CO has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: CO has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CO's debt is covered by short term assets.


Next Steps

Dividend

What is Global Cord Blood's current dividend yield, its reliability and sustainability?

2.59%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: CO's dividend (2.59%) is higher than the bottom 25% of dividend payers in the US market (2.05%).

High Dividend: CO's dividend (2.59%) is low compared to the top 25% of dividend payers in the US market (5.71%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, CO has been paying a dividend for less than 10 years.

Growing Dividend: CO's dividend payments have increased, but the company has only paid a dividend for 2 years.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average board tenure


CEO

Tina Zheng (47yo)

no data

Tenure

CN¥465,362

Compensation

Ms. Ting Zheng, also known as Tina, serves as the Chief Executive Officer and Chief Executive Officer of Beijing Division of China Cord Blood Corporation and had been its Interim Chief Executive Officer of ...


CEO Compensation Analysis

Compensation vs Market: Tina's total compensation ($USD465.36K) is below average for companies of similar size in the US market ($USD2.25M).

Compensation vs Earnings: Tina's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Ting Zheng
Chairperson no dataCN¥465.36kno data
Bing Chuen Chen
CFO & Directorno dataCN¥465.36k0.38% CN¥1.3m
Mark D. Chen
Independent Non-Executive Directorno datano datano data
Yungang Lu
Independent Non-Executive Director10.83yrsno datano data
Jennifer Weng
Independent Non-Executive Director10.83yrsno datano data
Siu Chuen Cheng
Independent Non-Executive Director0.17yrno datano data
Ping Xu
Non-Executive Director2.25yrsno datano data
Jack Chow
Independent Non-Executive Director0.42yrno datano data

2.3yrs

Average Tenure

47yo

Average Age

Experienced Board: CO's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.


Top Shareholders

Company Information

Global Cord Blood Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Global Cord Blood Corporation
  • Ticker: CO
  • Exchange: NYSE
  • Founded:
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$353.714m
  • Shares outstanding: 121.55m
  • Website: https://www.globalcordbloodcorp.com

Number of Employees


Location

  • Global Cord Blood Corporation
  • Bank of China Tower
  • 48th Floor
  • Central
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CONYSE (New York Stock Exchange)YesOrdinary SharesUSUSDJul 2009
6CBDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2009

Biography

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2019, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership). 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/06 01:49
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.